Read + Share
Schectman JM. In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced
disease progression or death at 45 d. Ann Intern Med 2023 Feb 7. doi: 10.7326/J22-0118.
PMID: 36745891
|
 |
|
Schectman JM. In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced
disease progression or death at 45 d. Ann Intern Med 2023 Feb 7. doi: 10.7326/J22-0118.
PMID: 36745891
|
|
|
|